Overland Park, United States
Ronawk, founded in 2019 and headquartered in the United States, is revolutionizing the biopharma industry with its innovative Bio-OS™ platform. This biological operating system aims to transform biological manufacturing much like Nvidia™ GPUs did for AI computing.
By addressing the shortcomings of existing cell culture tools, which were primarily designed for microbes, Ronawk offers a compelling solution. Bio-OS™ consists of three integrated layers: modular hardware, standardized software, and living wetware. This trifecta enables a conducive environment for various cells, yielding predictable results for researchers and scalable pathways for manufacturers to develop future therapies.
Operating at the intersection of Biopharma, Biotechnology, and Health Care, Ronawk empowers the next wave of therapeutic innovation. The company recently secured a $6.50M Series A investment in August 2023, underscoring its potential and attractiveness to investors seeking to tap into the future of biotechnological advancements.
